Summit Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-1.08B | $-221.3M | $-614.9M | $-78.8M | $-88.6M | $-52.7M | $-29.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $146.0K | $89.0K | $198.0K | $349.0K | $330.0K | $302.0K | $321.0K |
| Amortization | — | $0 | $0 | $914.0K | $1.0M | $1.3M | $970.0K |
| Stock-Based Compensation | $732.4M | $51.0M | $14.1M | $11.9M | $12.8M | $1.8M | $845.0K |
| Net Cash from Operating Activities | $-322.9M | $-142.1M | $-76.8M | $-41.6M | $-72.6M | $-48.1M | $-20.8M |
| Investing Activities | |||||||
| Capital Expenditures | $657.0K | $139.0K | $128.0K | $624.0K | $306.0K | $421.0K | $205.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-174.3M | $-205.3M | $-587.8M | $-624.0K | $-306.0K | $-421.0K | $-341.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | $0 | $0 |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $617.5M | $381.2M | $86.5M | $620.2M | $77.9M | $50.6M | $49.5M |
| Net Change in Cash | $120.4M | $33.8M | $-577.2M | $576.8M | $5.4M | $2.6M | $28.6M |
| Free Cash Flow | $-323.6M | $-142.2M | $-76.9M | $-42.2M | $-72.9M | $-48.5M | $-21.0M |